Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EQ 101

Next Previous
Drug Profile

EQ 101

Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40; EQ-101

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioniz
  • Developer Bioniz; Equillium
  • Class Antineoplastics; Antivirals; Peptides; Skin disorder therapies
  • Mechanism of Action Interleukin 15 receptor antagonists; Interleukin 2 receptor antagonists; Interleukin 9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alopecia areata; Cutaneous T-cell lymphoma; Large granular lymphocytic leukaemia; T-cell leukaemia; Vitiligo
  • Discontinued Tropical spastic paraparesis

Most Recent Events

  • 23 Apr 2025 Suspended - Phase-II for Alopecia areata in USA, Australia, New Zealand (IV) due to limited financial resources
  • 23 Apr 2025 Suspended - Phase-II for Large granular lymphocytic leukaemia (Second-line therapy or greater) in USA (IV) due to limited financial resources
  • 23 Apr 2025 Suspended - Phase-II for T-cell leukaemia in USA (IV) due to limited financial resources

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top